Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS

Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease

(2011) Johannes-Peter Stasch et al.   CIRCULATION

Emerging drugs for pulmonary hypertension

(2010) Reda E Girgis   EXPERT OPINION ON EMERGING DRUGS

Survival after pulmonary thromboendarterectomy: Effect of residual pulmonary hypertension

(2010) Darren H. Freed et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations

(2009) Douglas M. Fast et al.   AAPS Journal

Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

(2009) et al.   EUROPEAN HEART JOURNAL

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

(2009) F. Grimminger et al.   EUROPEAN RESPIRATORY JOURNAL

Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension

(2008) Robin Condliffe et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

(2008) Reiner Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY